Company attributes
Venture Capital Firm attributes
Other attributes
Karolinska Development is a venture capital firm in Sweden that focuses on identifying medical innovations and supporting the creation and growth of companies. Founded 2003 in Solna, Stockholms Lan, Sweden, it invests in series C, venture rounds, corporate rounds and series A rounds. Its portfolio companies include Karolinska. Karolinska Development has made 14 investments. Their most recent investment was on November 30, 2018, when Aprea raised €50M. Karolinska has had two exits, the most notable of which include Aprea and Asarina Pharma. Although Karolinska Development has a flexible exit strategy, pharmaceutical products are, for two reasons, preferably exited at Phase II. First a successful Phase II study indicates that the pharmaceutical has an effect on patients, which is an important value-enhancing factor when negotiating out-licensing or sales. Secondly, finalizing product development and undertaking Phase III clinical trials frequently requires very large patient populations.
